abbvie glp-1 Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic AbbVie budgets $380M for obesity

Food 4:199

Diarrhea Diarrhea affects about 30% to 35% of people taking tirzepatide

After an IV course, if continued therapy is needed, patients are often switched to oral ALA supplements (since oral forms are readily available for maintenance therapy)

doi: 10.1016/j.talanta.2018.06.023 71 Theratechnologies Inc

Mold Immune Reactivity IgE: Cladosporium herbarum : 2.4 Penicillium chrysogen : 4.1 Remaining panel: negative IgG: Broad elevation across multiple molds (including Cladosporium, Aspergillus, Setomelanomma, Curvularia ) Clinical Interpretation of Findings Indicated: Strong mold-specific immune sensitization Intermediate Intervention: Immune Modulation and Neuroregulation Oral immunotherapy (1 5 drops over 5 weeks) L-theanine 200 mg three times daily Clinical Response: Substantial reduction in anxiety Improved cognitive clarity Improved emotional stability Escalation of Binding Therapy Cholestyramine introduced Clinical Response (2 months): Resolution of fatigue Resolution of pain Improved GI symptoms Reduced food intolerance Final Intervention: Glutathione IV glutathione titrated from 1000 mg 3000 mg over 6 weeks Clinical Response: Resolution of insomnia Outcome Neuropsychiatric symptoms resolved Systemic symptoms improved Sleep normalized Discussion Objective improvement may precede symptom resolution Early reductions in C4a and TGF-1 suggest physiologic improvement before full clinical recovery

Who Should Exercise Caution Pregnant/Breastfeeding: Consult a healthcare professional